Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 99.91% is 236% above its 5-year average of 29.75%, near the high end of its 5-year range (-99154.10%–100.00%).
As of the fiscal period ended Tuesday, June 30, 2026. 0.79% above its 12-month average of 99.13%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 100.00%.
GROSS MARGIN
99.91%
GROSS MARGIN AVG TTM
99.13%
GROSS MARGIN AVG 3Y
53.55%
GROSS MARGIN AVG 5Y
29.75%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+0.79%
CURRENT VS 3Y AVG
+86.57%
CURRENT VS 5Y AVG
+235.83%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
44.24%
median of 454 covered companies
CURRENT VS SECTOR MEDIAN
+125.84%
vs the sector median at left
Coya Therapeutics, Inc.
Market Cap
$113.77M
Gross Margin
99.91%
TTM Avg
99.13%
3Y Avg
53.55%
5Y Avg
29.75%
Market Cap
$114.24M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$111.17M
Gross Margin
99.54%
TTM Avg
49.77%
3Y Avg
24.89%
5Y Avg
16.59%
Market Cap
$116.59M
Gross Margin
-7075.00%
TTM Avg
-9131.25%
3Y Avg
-4667.52%
5Y Avg
-3111.68%
Market Cap
$117.43M
Gross Margin
89.22%
TTM Avg
94.61%
3Y Avg
97.31%
5Y Avg
-2138.81%
Market Cap
$118.02M
Gross Margin
67.34%
TTM Avg
64.03%
3Y Avg
72.89%
5Y Avg
33.80%
Market Cap
$109.49M
Gross Margin
33.94%
TTM Avg
48.53%
3Y Avg
56.75%
5Y Avg
59.91%
Market Cap
$118.50M
Gross Margin
11.17%
TTM Avg
22.02%
3Y Avg
17.41%
5Y Avg
13.61%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Coya Therapeutics, Inc. (COYA) | $113.77M | 99.91% | 99.13% | 53.55% | 29.75% |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $114.24M | 0.00% | 0.00% | 0.00% | 0.00% |
| Black Diamond Therapeutics, Inc. (BDTX)vs › | $111.17M | 99.54% | 49.77% | 24.89% | 16.59% |
| Genelux Corporation (GNLX)vs › | $116.59M | -7075.00% | -9131.25% | -4667.52% | -3111.68% |
| Foghorn Therapeutics Inc. (FHTX)vs › | $117.43M | 89.22% | 94.61% | 97.31% | -2138.81% |
| Immunic, Inc. (IMUX)vs › | $109.93M | 0.00% | 0.00% | 0.00% | 0.00% |
| Caribou Biosciences, Inc. (CRBU)vs › | $118.02M | 67.34% | 64.03% | 72.89% | 33.80% |
| Apyx Medical Corporation (APYX)vs › | $109.49M | 33.94% | 48.53% | 56.75% | 59.91% |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $118.50M | 11.17% | 22.02% | 17.41% | 13.61% |
| BGM Group Ltd. (BGM)vs › | $118.63M | 12.79% | 14.59% | 10.64% | 11.25% |
Gross Margin
99.9%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 100.00% |
| 2026-03-31 | 100.00% |
| 2025-12-31 | 100.00% |
| 2025-09-30 | 99.81% |
| 2025-06-30 | 95.82% |
| 2025-03-31 | -1921.87% |
| 2024-12-31 | -99154.10% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | -33.31% |
| 2024-03-31 | -2374.15% |
| 2023-12-31 | 73.18% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
